Once again, it’s debunking time.
The New York Post headline — “Bombshell cannabis study reveals hidden risks of medical pot” — is a textbook example of how cannabis continues to be treated differently from almost every other therapeutic substance in mainstream media. The problem is not the study itself, but what this media outlet does with it.
The UCLA-led review Updated in JAMA does not conclude that medical cannabis is dangerous, fraudulent, or a failed therapy. What it actually concludes is something far more modest and far more common in medicine: that the evidence base is uneven, incomplete, and in need of better research.
That is something cannabis advocates have been saying for decades, and it is an argument for expanding research, not restricting access.
What the Study Actually Says (and What It Doesn’t)
Dr. Michael Hsu, the study’s lead author, states plainly: “Further research is crucial to better understand the potential benefits and risks of medical cannabis.”
The review examined more than 2,500 studies Updated between 2010 and 2025, narrowing its focus to roughly 120 higher-quality papers. Its conclusions are careful and measured.
The authors found strong evidence for FDA-approved cannabinoid medicines in limited contexts such as chemotherapy-induced nausea, HIV-related appetite loss, and rare pediatric epilepsies. For other common uses, including chronic pain, anxiety, and insomnia, the evidence is mixed or insufficient, not disproven. The review also notes potential risks associated with high-potency, frequent use, particularly among adolescents or people with certain vulnerabilities.
Crucially, the authors acknowledge that the review is not systematic, lacks formal bias assessment, and relies in part on observational studies that are vulnerable to confounding factors.
Most importantly, the paper calls for more rigorous research, not restriction, prohibition, or panic.
How the Media Distorts That Message
The New York Post follows a familiar pattern, treating scientific uncertainty as evidence of danger.
Rather than explaining that cannabis research has been structurally limited for decades, and that product variability makes standardization difficult, the article reframes uncertainty as “hidden risks” and “overestimated benefits,” implying deception or irresponsibility.
You cannot claim benefits are “overestimated” when the core issue is that they have not been studied at scale. Lack of evidence is not evidence of lack, especially when real-world use spans millions of patients.
If this logic were applied consistently across medicine, the headlines would be absurd.
We could just as easily write “Antidepressants overhyped” or “Psychiatry exposed” because outcomes vary and effect sizes are modest.
In reality, that kind of variability is normal in medicine and usually prompts better research, not moral panic.
Risk Is Not Unique to Cannabis
The review notes elevated risks associated with frequent, high-potency use, particularly among adolescents or people with cardiovascular or psychiatric vulnerabilities.
This is not unique to cannabis. Similar cautions exist for alcohol, benzodiazepines, opioids, stimulants, and even antidepressants.
Yet those substances are rarely framed as “bombshell risks” every time new data emerges.
The study itself recommends screening, patient education, dosage awareness, and clinician oversight. In other words, standard harm reduction.
The most important takeaway is not that cannabis does not work, but that cannabis research has been fragmented and underfunded due to decades of prohibition. Researchers are still trying to study a complex plant using tools designed for single-molecule drugs.
If I were writing the headline, it might read: “Major review highlights need for stronger cannabis research as use outpaces evidence.”
But that doesn’t generate fear, so it probably wouldn’t get the clicks.
